An ancient medicine for a modern problem. Xingxiao Pill (XXP) is a classical Traditional Chinese Medicine (TCM) prescription composed of four natural ingredients: Realgar (a mineral form of arsenic sulfide), Moschus (musk), Boswellia sacra (frankincense), and Commiphora myrrha (myrrh). It has been used clinically in China to improve quality of life for lung cancer patients.
Prior evidence of antitumor activity. Earlier research had demonstrated that XXP can suppress antitumor immunity and inhibit tumor blood vessel formation (angiogenesis) in lung cancer. However, the specific molecular mechanisms through which it attacks cancer cells remained poorly understood - the gap this study aimed to fill.
Why fat metabolism matters in cancer. Cancer cells need enormous amounts of energy and raw materials to grow rapidly. Fatty acid biosynthesis - the process by which cells manufacture fats from simpler molecules - has emerged as a critical metabolic pathway for cancer cell survival and proliferation. Abnormal fat metabolism is closely linked to NSCLC development.
Study goal. The researchers set out to systematically evaluate how XXP affects fatty acid metabolism in NSCLC using a mouse tumor model, cell culture experiments, and bioinformatics analysis - combining traditional medicine with modern molecular biology to uncover the drug's mechanisms.
Animal tumor model. Lewis lung carcinoma (LLC) cells were transplanted under the skin of male mice to create a lung cancer model. Animals received XXP by oral gavage at low, medium, or high doses for 15 days, with a cisplatin treatment group as a positive control. Tumor size, weight, and tissue characteristics were monitored throughout.
Cell culture experiments. Two lung cancer cell lines - human A549 cells and mouse LLC cells - were treated with XXP at different concentrations to measure effects on cell viability, proliferation, cell cycle progression, apoptosis (programmed cell death), and migration. These experiments revealed the drug's direct effects on cancer cell biology.
Chemical fingerprinting of XXP. Advanced mass spectrometry (UPLC-Q-Orbitrap HRMS) was used to identify the specific chemical compounds present in XXP. This analysis revealed three primary active components: Myrrhone (from myrrh), Poricoic acid B, and 11-keto-beta-boswellic acid, plus 66 additional active compounds identified through network pharmacology databases.
Bioinformatics and transcriptome sequencing. Multiple TCM and genomic databases were queried to identify potential molecular targets where XXP could interact with lung cancer biology. RNA sequencing of tumor tissues from treated and untreated mice identified 237 genes with changed expression levels, revealing which biological pathways XXP modulates.
Significant tumor growth inhibition. In the mouse lung carcinoma model, high-dose XXP significantly reduced tumor volume by day 12, matching the effect seen in the cisplatin (chemotherapy) control group. The tumor volume-to-body-weight ratio - a sensitive indicator of cancer progression - was also markedly reduced in the high-dose group.
Tissue-level changes in tumor cells. Microscopic examination (H&E staining) of tumor tissue from XXP-treated mice revealed smaller cell nuclei, reduced nuclear-to-cytoplasmic ratios, a vacuolated appearance of tumor cells, and decreased immune cell infiltration - all changes consistent with less aggressive, less invasive tumor biology.
Body weight preserved; organ indices normal. Despite its antitumor activity, XXP did not cause weight loss in treated mice. Importantly, organ indices for the spleen, lungs, and thymus remained comparable across groups, while the cisplatin-treated positive control showed decreased liver index - highlighting XXP's favorable safety profile relative to conventional chemotherapy.
Supporting the clinical safety record. The authors noted that previous clinical trials in NSCLC patients had already demonstrated XXP's safety and tolerability. The mouse data added mechanistic depth to support what was already known from human experience with this traditional medicine.
Dose-dependent reduction in cancer cell viability. XXP reduced the viability of both A549 (human) and LLC (mouse) lung cancer cells in a concentration-dependent manner. The IC50 values - the concentration needed to kill half the cells - were 0.65 mg/mL for A549 and 0.47 mg/mL for LLC cells, indicating meaningful potency against both cell lines.
Cell cycle disruption. Treatment with XXP altered the normal cell cycle progression in both cell lines, causing a decrease in cells in the G1 phase (preparation for DNA replication) and an increase in cells arrested in the G2 phase (post-replication checkpoint). This arrest prevents cells from completing division and producing new cancer cells.
Induction of programmed cell death. At IC25 and IC50 concentrations, XXP significantly induced apoptosis in A549 human lung cancer cells. A trend toward apoptosis was also observed in LLC cells, though the effect did not reach statistical significance in that cell line, suggesting slightly different sensitivity between the two cell types.
Suppression of cancer cell migration. XXP markedly reduced the migratory capacity of both A549 and LLC cells in transwell assay experiments. Reduced cancer cell migration is clinically significant because cell movement is a key first step in cancer spread (metastasis) to other organs.
1550 molecular targets identified. Network pharmacology and bioinformatics analysis identified 1,550 overlapping targets between XXP's active compounds and lung cancer biology. The top 20 relevant signaling pathways included lipid metabolism, the PI3K/AKT pathway, and the mTOR signaling pathway - all established cancer-driving networks.
Core molecular targets. CytoNCA network analysis identified 19 core targets through which XXP likely exerts its effects, including AKT1 (a key cell survival kinase), TP53 (the well-known tumor suppressor gene), and others that regulate cell growth and metabolism. These represent the molecular bridges between XXP's chemical components and cancer biology.
Transcriptome sequencing confirms lipid metabolism as a key pathway. RNA sequencing of tumor tissues from high-dose XXP-treated and untreated mice identified 237 differentially expressed genes. KEGG pathway analysis consistently highlighted lipid metabolism as a major pathway affected - appearing in both upregulated and downregulated gene signatures.
Convergence of computational and experimental evidence. The agreement between bioinformatics predictions (which pathways XXP should target based on its chemical composition) and experimental transcriptome findings (which pathways actually changed in treated tumors) strengthened confidence that XXP's anticancer effects are channeled primarily through lipid metabolism and the PI3K/AKT/mTOR signaling axis.
Reduced lipid accumulation in cancer cells. Oil Red O staining - a technique that marks fat droplets red - showed that XXP treatment significantly reduced lipid droplet accumulation in A549 cancer cells at both tested concentrations. Cancer cells normally accumulate large amounts of fat to fuel their rapid growth; XXP starves them of this resource.
Lower levels of key fat molecules. XXP significantly reduced intracellular levels of total cholesterol (TC), triglycerides (TG), and free fatty acids in A549 cells. These molecules are direct products of fatty acid biosynthesis, and their reduction confirms that XXP is actively suppressing the fat-making machinery of cancer cells.
SREBP1 and FASN: the key enzymes targeted. XXP was found to downregulate two critical regulators of fatty acid synthesis: SREBP1 (a transcription factor that switches on fat production genes) and FASN (fatty acid synthase, the main enzyme that actually manufactures fatty acids). Both are overexpressed in lung cancer and associated with worse prognosis.
PI3K/AKT/mTOR pathway suppression. Western blotting showed that XXP reduced the expression and phosphorylation (activation) of PI3K, AKT, and mTOR proteins. This signaling cascade normally drives both cell growth and fatty acid production - by shutting it down, XXP simultaneously targets cell survival and metabolic support for tumor growth.
A validated dual mechanism. This study demonstrated that Xingxiao Pill suppresses NSCLC through two interconnected mechanisms: inhibiting fatty acid biosynthesis (by reducing SREBP1 and FASN) and suppressing the PI3K/AKT/mTOR signaling pathway. These pathways reinforce each other, as PI3K/AKT/mTOR signaling normally promotes FASN and SREBP1 expression.
Confirmation of pathway specificity. Using SC79, a drug that artificially activates the AKT protein, the researchers showed that XXP could counteract this activation and restore reduced SREBP1, FASN, and downstream signaling - directly demonstrating that the PI3K/AKT/mTOR pathway is the mechanism of action, not just a correlative finding.
Implications for TCM research. This work exemplifies a rigorous modern approach to investigating traditional medicines, using cell biology, genomics, and animal models to identify specific molecular targets. The findings support the idea that TCM formulations can harbor novel therapeutic mechanisms that may complement or enhance conventional cancer treatments.
Limitations and future work. The study lacked direct genetic manipulation (such as CRISPR gene editing) to definitively prove pathway causality. Future research should include gene silencing experiments, additional NSCLC cell lines for broader validation, and ideally clinical data comparing XXP to standard treatments. These steps would be needed before clinical translation could be pursued.